Complement receptor 2 polymorphisms associated with systemic lupus erythematosus modulate alternative splicing

[1]  B. Frey,et al.  Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing , 2008, Nature Genetics.

[2]  Jyoti K. Shah,et al.  Differential expression of 24 , 426 human alternative splicing events and predicted cis-regulation in 48 tissues and cell lines , 2011 .

[3]  Eric T. Wang,et al.  Alternative Isoform Regulation in Human Tissue Transcriptomes , 2008, Nature.

[4]  Marta E Alarcón-Riquelme,et al.  Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci , 2008, Nature Genetics.

[5]  Jacek Majewski,et al.  Genome-wide analysis of transcript isoform variation in humans , 2008, Nature Genetics.

[6]  T. Shimoda,et al.  Association of polymorphisms in complement component C3 gene with susceptibility to systemic lupus erythematosus. , 2008, Rheumatology.

[7]  K. J. Hertel,et al.  Combinatorial Control of Exon Recognition* , 2008, Journal of Biological Chemistry.

[8]  Rolf Backofen,et al.  Pre-mRNA Secondary Structures Influence Exon Recognition , 2007, PLoS genetics.

[9]  Guey-Shin Wang,et al.  Splicing in disease: disruption of the splicing code and the decoding machinery , 2007, Nature Reviews Genetics.

[10]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[11]  B. Croker,et al.  Augmentation of NZB Autoimmune Phenotypes by the Sle1c Murine Lupus Susceptibility Interval1 , 2007, The Journal of Immunology.

[12]  R. Cantor,et al.  Association of a common complement receptor 2 haplotype with increased risk of systemic lupus erythematosus , 2007, Proceedings of the National Academy of Sciences.

[13]  A. Kornblihtt.  Chromatin, transcript elongation and alternative splicing , 2006, Nature Structural &Molecular Biology.

[14]  M. Farrall,et al.  Integrating Case‐control and TDT Studies , 2005 .

[15]  M Farrall,et al.  Integrating case-control and TDT studies. , 2005, Annals of human genetics.

[16]  V. Holers,et al.  Complement receptors and the shaping of the natural antibody repertoire , 2005, Springer Seminars in Immunopathology.

[17]  B. Tsao.  Update on human systemic lupus erythematosus genetics , 2004, Current opinion in rheumatology.

[18]  S. Gallati,et al.  The role of common single‐nucleotide polymorphisms on exon 9 and exon 12 skipping in nonmutated CFTR Alleles , 2004, Human mutation.

[19]  G. Tsokos,et al.  NF-κB Regulates the Expression of the Human Complement Receptor 2 Gene1 , 2002, The Journal of Immunology.

[20]  L. Morel,et al.  A Role for the Cr2 Gene in Modifying Autoantibody Production in Systemic Lupus Erythematosus1 , 2002, The Journal of Immunology.

[21]  V. Holers,et al.  Functional Analysis of the Human Complement Receptor 2 (CR2/CD21) Promoter: Characterization of Basal Transcriptional Mechanisms1 , 2002, The Journal of Immunology.

[22]  V. Holers,et al.  CR2/CD21 Proximal Promoter Activity Is Critically Dependent on a Cell Type-Specific Repressor1 , 2001, The Journal of Immunology.

[23]  D. Karp,et al.  Cr2, a candidate gene in the murine Sle1c lupus susceptibility locus, encodes a dysfunctional protein. , 2001, Immunity.

[24]  Christopher J. Lee,et al.  Genome-wide detection of alternative splicing in expressed sequences of human genes , 2001, Nucleic Acids Res..

[25]  G. Tsokos,et al.  Multiple Transcription Factors Regulate the Inducible Expression of the Human Complement Receptor 2 Promoter1 , 2001, The Journal of Immunology.

[26]  K. Makar,et al.  A site in the complement receptor 2 (CR2/CD21) silencer is necessary for lineage specific transcriptional regulation. , 2001, International immunology.

[27]  K. Blenman,et al.  Genetic reconstitution of systemic lupus erythematosus immunopathology with polycongenic murine strains. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[28]  C. Goodnow,et al.  A critical role for complement in maintenance of self-tolerance. , 1998, Immunity.

[29]  J. Cyster,et al.  Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection. , 1998, Immunity.

[30]  M. Dehoff,et al.  An intronic silencer regulates B lymphocyte cell- and stage-specific expression of the human complement receptor type 2 (CR2, CD21) gene. , 1998, Journal of immunology.

[31]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[32]  I. Melchers,et al.  Analysis of the human CD21 transcription unit reveals differential splicing of exon 11 in mature transcripts and excludes alternative splicing as the mechanism causing solubilization of CD21. , 1997, Molecular immunology.

[33]  J. Banchereau,et al.  Follicular Dendritic Cells Specifically Express the Long CR2/CD21 Isoform , 1997, The Journal of experimental medicine.

[34]  H. Marquart,et al.  Complement receptor expression and activation of the complement cascade on B lymphocytes from patients with systemic lupus erythematosus (SLE) , 1995, Clinical and experimental immunology.

[35]  Y. S. Choi,et al.  Activation and proliferation of follicular dendritic cell-like cells by activated T lymphocytes. , 1994, Journal of immunology.

[36]  D. Fearon,et al.  Functional dissection of the CD21/CD19/TAPA-1/Leu-13 complex of B lymphocytes , 1993, The Journal of experimental medicine.

[37]  E. Levy,et al.  T lymphocyte expression of complement receptor 2 (CR2/CD21): a role in adhesive cell‐cell interactions and dysregulation in a patient with systemic lupus erythematosus (SLE) , 1992, Clinical and experimental immunology.

[38]  J. Bonnefoy,et al.  CD21 is a ligand for CD23 and regulates IgE production , 1992, Nature.

[39]  S. Mathur,et al.  Epstein Barr virus/complement C3d receptor is an interferon alpha receptor. , 1991, The EMBO journal.

[40]  M. Reth,et al.  Exon trap cloning: using PCR to rapidly detect and clone exons from genomic DNA fragments. , 1990, Nucleic acids research.

[41]  J. Harley,et al.  Genomic organization and polymorphisms of the human C3d/Epstein-Barr virus receptor. , 1989, The Journal of biological chemistry.

[42]  D. Fearon,et al.  Structure of the human B lymphocyte receptor for C3d and the Epstein- Barr virus and relatedness to other members of the family of C3/C4 binding proteins [published erratum appears in J Exp Med 1988 Nov 1;168(5):1953-4] , 1988, The Journal of experimental medicine.

[43]  G. Nemerow,et al.  Molecular cloning of the cDNA encoding the Epstein-Barr virus/C3d receptor (complement receptor type 2) of human B lymphocytes. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[44]  P. Schur,et al.  Decreased expression of the C3b/C4b receptor (CR1) and the C3d receptor (CR2) on B lymphocytes and of CR1 on neutrophils of patients with systemic lupus erythematosus. , 1986, Arthritis and rheumatism.

[45]  P. A. Biro,et al.  Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[46]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.